Loading...
Market
Number of Voltapraz prescriptions in India by end of 2024
3
Resolution / Starting Odds
Less than 1 million • 33%
1 million to 2 million • 33%
More than 2 million • 33%
Healthcare market research reports or prescription tracking services
Story
Takeda Signs Licensing Agreements with Cipla and Sun Pharma for Vonoprazan (Voltapraz) in India
Jun 21, 2024, 04:48 AM
Takeda Pharmaceutical has signed licensing agreements with both Cipla and Sun Pharmaceutical to commercialize the gastrointestinal drug Vonoprazan in India. Cipla and Sun Pharma will market the drug under the brand name 'Voltapraz' in dosages of 10 mg and 20 mg. The agreements are non-exclusive, allowing both companies to distribute the drug in the Indian market. The announcement was made through an exchange filing.
View original story
Similar markets
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%